OXOlife: Funding, Investors & Team (Sep 2026)
Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.
OXOlife has raised $2.5M across 1 funding round on record, the most recent an undisclosed round of $2.5M announced in Dec 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OXOlife Company Profile and Key Stats
Latest funding round on record: Dec 2022.
OXOlife Funding Rounds
OXOlife Founders and Leadership Team
No contact details are on record for this team yet.
OXOlife Funding Compared to Other Biotechnology Startups
OXOlife's latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OXOlife in Biotechnology and San Quírico Safaja
Companies Similar to OXOlife
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun…
OXOlife Funding FAQs
What does OXOlife do?
Oxolife : enhancing female fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are currently developing an innovative treatment (OXO-001) to enhance female fertility success through acting on peri/post implantatory process. Additionally, OXO-001 restores ovulation. OXO-001 is a first in class drug due to its mechanism of action, solving an unmet need, since no solution drug in the embryo implantation market segment is available today. Is envisioned that the first phase II clinical trial will be completed by 2023. OXO-001 is protected by three different patents under the same umbrella which cover all the possible uses for female fertility. Oxolife’s team is leaded by Agnès Arbat, Medical Doctor (Co-founder and CEO) and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Both accumulate a wide experience in the Women’s health pharmaceutical industry. The team has been supported by Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.
How much funding has OXOlife raised?
OXOlife has raised $2.5M across 1 round on record. The most recent is an undisclosed round of $2.5M announced in Dec 2022.
When did OXOlife last raise funding?
OXOlife's most recent funding round on record is an undisclosed round of $2.5M, announced in Dec 2022.
Who is the CEO of OXOlife?
Agnes Arbat is listed as CEO at OXOlife.
Where is OXOlife headquartered?
OXOlife is based in San Quírico Safaja, Catalonia, Spain.
How many employees does OXOlife have?
OXOlife is in the 1-10 employee band.
How does OXOlife's funding compare to other Biotechnology startups?
OXOlife's latest round of $2.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's OXOlife Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OXOlife is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.